JP2005533005A5 - - Google Patents

Download PDF

Info

Publication number
JP2005533005A5
JP2005533005A5 JP2003577881A JP2003577881A JP2005533005A5 JP 2005533005 A5 JP2005533005 A5 JP 2005533005A5 JP 2003577881 A JP2003577881 A JP 2003577881A JP 2003577881 A JP2003577881 A JP 2003577881A JP 2005533005 A5 JP2005533005 A5 JP 2005533005A5
Authority
JP
Japan
Prior art keywords
group
inhibitor
drug
inflammatory
cox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003577881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533005A (ja
JP4733350B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/008287 external-priority patent/WO2003080053A1/en
Publication of JP2005533005A publication Critical patent/JP2005533005A/ja
Publication of JP2005533005A5 publication Critical patent/JP2005533005A5/ja
Application granted granted Critical
Publication of JP4733350B2 publication Critical patent/JP4733350B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003577881A 2002-03-18 2003-03-17 ケモカイン媒介疾患の併用治療 Expired - Fee Related JP4733350B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36531402P 2002-03-18 2002-03-18
US60/365,314 2002-03-18
PCT/US2003/008287 WO2003080053A1 (en) 2002-03-18 2003-03-17 Combination treatments for chemokine-mediated diseases

Publications (3)

Publication Number Publication Date
JP2005533005A JP2005533005A (ja) 2005-11-04
JP2005533005A5 true JP2005533005A5 (enExample) 2010-05-27
JP4733350B2 JP4733350B2 (ja) 2011-07-27

Family

ID=28454639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003577881A Expired - Fee Related JP4733350B2 (ja) 2002-03-18 2003-03-17 ケモカイン媒介疾患の併用治療

Country Status (14)

Country Link
US (2) US20040053953A1 (enExample)
EP (1) EP1485089B1 (enExample)
JP (1) JP4733350B2 (enExample)
CN (1) CN100444839C (enExample)
AR (1) AR040400A1 (enExample)
AU (1) AU2003220384B2 (enExample)
BR (1) BR0308739A (enExample)
CA (1) CA2479126C (enExample)
MX (1) MXPA04009127A (enExample)
NO (1) NO20044402L (enExample)
NZ (1) NZ535314A (enExample)
TW (2) TW200808314A (enExample)
WO (1) WO2003080053A1 (enExample)
ZA (1) ZA200407339B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
KR20100008794A (ko) * 2001-04-16 2010-01-26 쉐링 코포레이션 Cxc-케모카인 수용체 리간드로서의 3,4-이치환된 사이클로부텐-1,2-디온
JP2005505595A (ja) 2001-10-12 2005-02-24 シェーリング コーポレイション Cxc−ケモカインレセプターアンタゴニストとしての3,4−二置換マレイミド化合物
US6878709B2 (en) 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
EP1551818B1 (en) * 2002-10-09 2009-02-04 Schering Corporation Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands
US8524148B2 (en) * 2002-11-07 2013-09-03 Abbott Laboratories Method of integrating therapeutic agent into a bioerodible medical device
US8221495B2 (en) * 2002-11-07 2012-07-17 Abbott Laboratories Integration of therapeutic agent into a bioerodible medical device
KR20050086430A (ko) * 2002-11-07 2005-08-30 아보트 러보러터리즈 혼합되지 않은 개별 방울로서 다수의 약을 가진 보형물
DE602004025458D1 (de) 2003-04-18 2010-03-25 Schering Corp SYNTHESE VON 2-HYDROXY-N,N-DIMETHYL-3-ii2-i1(R)-(5-METHYL-2-FURANYL)PROPYL AMINO -3,4-DIOXO-1-CYCLOBUTEN-1-YL AMINO BENZAMID
US7338968B2 (en) * 2003-12-19 2008-03-04 Schering Corporation Thiadiazoles AS CXC- and CC- chemokine receptor ligands
WO2005068460A1 (en) * 2003-12-22 2005-07-28 Schering Corporation Isothiazole dioxides as cxc- and cc- chemokine receptor ligands
CN1914187B (zh) 2004-01-30 2012-01-25 先灵公司 Cxc趋化因子受体配位体的结晶多晶型物
DE102004016179A1 (de) * 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
ZA200608572B (en) * 2004-04-16 2008-06-25 Genentech Inc Assay for antibodies
CN1984899B (zh) * 2004-05-12 2011-07-27 先灵公司 Cxcr1和cxcr2趋化因子拮抗剂
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
ATE486078T1 (de) * 2005-06-29 2010-11-15 Schering Corp 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors
WO2007002764A2 (en) 2005-06-29 2007-01-04 Schering Corporation Di-substituted oxadiazoles as cxc-chemokine receptor ligands
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007146296A1 (en) * 2006-06-12 2007-12-21 Schering Corporation Pharmaceutical formulations and compositions of a selective antagonist of either cxcr2 or both cxcr1 and cxcr2 and methods of using the same for treating inflammatory disorders
JP2009542700A (ja) * 2006-07-07 2009-12-03 シェーリング コーポレイション Cxcケモカイン受容体リガンドとしての3,4−ジ置換シクロブテン−1,2−ジオン
US8450348B2 (en) * 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
MX2009013276A (es) 2007-06-06 2010-01-25 Novartis Ag Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
EP2178826B1 (en) * 2007-07-03 2017-05-17 Merck Sharp & Dohme Corp. Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
WO2010131145A1 (en) * 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
FR2961695B1 (fr) * 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
US20140170112A1 (en) * 2011-03-12 2014-06-19 Vicus Therapeutics, Llc Compositions for ameliorating systemic inflammation and methods for making and using them
WO2013030803A1 (en) 2011-09-02 2013-03-07 Novartis Ag Choline salt of an anti - inflammatory substituted cyclobutenedione compound
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
KR101306199B1 (ko) * 2012-01-31 2013-09-09 부산대학교 산학협력단 포스포리파아제 d 억제제를 유효성분으로 포함하는 골다공증 예방 및 치료용 약학적 조성물
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Cxcr2抑制劑
KR20200037857A (ko) * 2017-08-14 2020-04-09 알러간, 인코포레이티드 3,4-이치환된 3-시클로부텐-1,2-디온 및 그의 용도
MY202326A (en) 2017-09-14 2024-04-24 Daiichi Sankyo Co Ltd Compound having cyclic structure
ES3067325T3 (en) 2018-01-08 2026-05-21 Chemocentryx Inc Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
PE20211070A1 (es) 2018-09-21 2021-06-09 Pfizer Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas utiles como inhibidores de ccr6
CN112851635B (zh) * 2019-11-28 2022-09-16 中国医学科学院药物研究所 环状砜类化合物及其制备方法、用途和药物组合物
EP3868368A1 (en) * 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof
CN121693497A (zh) * 2023-11-03 2026-03-17 武汉朗来科技发展有限公司 作为ccr6拮抗剂的化合物、其药物组合物和用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1669798A1 (de) 1966-07-28 1971-08-26 Huels Chemische Werke Ag Verfahren zum Stabilisieren markomolekularer Polyacetale
FR1531943A (fr) 1966-07-28 1968-07-05 Huels Chemische Werke Ag Procédé pour stabiliser des poly-acétals macromoléculaires
DE2638855C3 (de) 1976-08-28 1980-04-24 Chemische Werke Huels Ag, 4370 Marl Verwendung von Quadratsäureamiden als Stabilisierungsmittel für geformte oder nicht geformte Kunststoffe
CS214745B2 (en) * 1976-08-28 1982-05-28 Huels Chemische Werke Ag Shaped and non-shaped products from plastic materials
DE3309655A1 (de) 1983-03-17 1984-09-20 Bayer Ag, 5090 Leverkusen 1,2,5-thiadiazol-1-oxide und 1,1-dioxide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS60255756A (ja) * 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
HU198696B (en) 1987-01-20 1989-11-28 Nissan Chemical Ind Ltd Process for producing 3/2h/-pyridazinon derivatives and pharmaceutical compositions containing them as active components
JPH02256668A (ja) 1988-12-20 1990-10-17 Nissan Chem Ind Ltd ピリダジノン誘導体
US5206252A (en) * 1992-05-08 1993-04-27 American Home Products Corporation Thiadiazolyl-amino derivatives of benzopyrans and indanes
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
US5354763A (en) 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5506252A (en) * 1993-11-17 1996-04-09 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5466712A (en) * 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
EP0796243B1 (en) 1994-11-16 1999-01-27 American Home Products Corporation Diaminocyclobutene-3,4-diones
CN1217660C (zh) * 1997-01-23 2005-09-07 史密丝克莱恩比彻姆公司 Il-8受体拮抗剂
US5840764A (en) * 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
AU6250298A (en) 1997-01-30 1998-08-25 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
AR015425A1 (es) * 1997-09-05 2001-05-02 Smithkline Beecham Corp Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion
AU5727899A (en) 1998-10-02 2000-04-26 Neurosearch A/S Diaminocyclobutene-3,4-dione derivatives, their preparation and use
JP2002527419A (ja) 1998-10-08 2002-08-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Gsk−3阻害物質としてのピロール−2,5−ジオン類
US6376555B1 (en) * 1998-12-04 2002-04-23 American Home Products Corporation 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers
JP2002532457A (ja) 1998-12-14 2002-10-02 アメリカン・ホーム・プロダクツ・コーポレイション Vla−4により仲介される白血球接着を阻害する3,4−ジアミノ−3−シクロブテン−1,2−ジオン誘導体
US6420396B1 (en) * 1998-12-16 2002-07-16 Beiersdorf Ag Biphenyl and biphenyl-analogous compounds as integrin antagonists
CN1334801A (zh) 1998-12-16 2002-02-06 拜尔公司 作为整联蛋白拮抗剂的新的联苯基和类似联苯基的化合物
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6586446B1 (en) 1999-10-15 2003-07-01 Bristol-Myers Squibb Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
AR033803A1 (es) * 2000-03-01 2004-01-07 Smithkline Beecham Corp Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
AU2001243351A1 (en) 2000-03-01 2001-09-12 Smith Kline Beecham Corporation Il-8 receptor antagonists
EP1274415A4 (en) 2000-03-14 2005-09-07 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
WO2001092202A1 (en) * 2000-05-30 2001-12-06 Smithkline Beecham Corporation Il-8 receptor antagonists
DE60230722D1 (de) * 2001-01-16 2009-02-26 Smithkline Beecham Corp Il-8-rezeptor-antagonisten
US20040048897A1 (en) * 2001-01-16 2004-03-11 Mccleland Brent Il-8 receptor antagonists
US20030204085A1 (en) 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
EP1355875A1 (en) * 2001-02-02 2003-10-29 Schering Corporation 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
KR20100008794A (ko) * 2001-04-16 2010-01-26 쉐링 코포레이션 Cxc-케모카인 수용체 리간드로서의 3,4-이치환된 사이클로부텐-1,2-디온
JP2005505595A (ja) 2001-10-12 2005-02-24 シェーリング コーポレイション Cxc−ケモカインレセプターアンタゴニストとしての3,4−二置換マレイミド化合物
US6878709B2 (en) 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
JP4836388B2 (ja) 2002-03-22 2011-12-14 第一三共株式会社 eNOS発現に起因する疾患の予防または治療薬
EP1551818B1 (en) 2002-10-09 2009-02-04 Schering Corporation Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands

Similar Documents

Publication Publication Date Title
CN100444839C (zh) 式(i)化合物在制备治疗化学激活物中介的疾病的药物中的应用
ES2337241T3 (es) Derivados de piperazina con actividad antagonista de receptores ccr1.
JP5746981B2 (ja) Jakキナーゼ調節キナゾリン誘導体、及びその使用方法
JP2005194283A5 (enExample)
JP2008512490A (ja) 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤
JP5901634B2 (ja) キナゾリン化合物及びその使用方法
JP2005509597A5 (enExample)
JP2016164177A5 (enExample)
JP2011506412A5 (enExample)
CN101511809A (zh) 作为cxc-趋化因子受体配体的3,4-二取代的环丁烯-1,2-二酮
JP2005515966A5 (enExample)
PT2642999T (pt) Métodos de tratamento que utilizam inibidores seletivos de bcl-2
JP2009522295A5 (enExample)
EP1881832A2 (en) Use of flibanserin in the treatment of chronic pain
JP2020530831A5 (enExample)
BR112021003613A2 (pt) conjugados de isoquinolina-esteróides e seus usos
JP2006515299A5 (enExample)
JP2009517411A5 (enExample)
JP2023526304A (ja) コロナウイルス感染症治療のためのtlr7/8拮抗薬
JP2005532256A5 (enExample)
JP2004529117A5 (enExample)
JP2023531930A5 (enExample)
JP2002326936A5 (enExample)
US5814649A (en) Preventive and remedy for type 1 allergic diseases
JP2005524666A5 (enExample)